These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 1139474

  • 1. Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
    Barbeau A.
    Can Med Assoc J; 1975 Jun 21; 112(12):1379-80. PubMed ID: 1139474
    [No Abstract] [Full Text] [Related]

  • 2. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P.
    Rev Prat; 1974 Mar 11; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract] [Full Text] [Related]

  • 3. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL, Rondot P, Cardon P.
    Therapie; 1977 Mar 11; 32(2):161-72. PubMed ID: 898124
    [No Abstract] [Full Text] [Related]

  • 4. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M, Miwa H, Kondo T.
    No To Shinkei; 2002 Feb 11; 54(2):127-32. PubMed ID: 11889758
    [Abstract] [Full Text] [Related]

  • 5. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
    Yokochi M, Kondo T, Hirayama K, Narabayashi H, Kuruma I.
    No To Shinkei; 1979 Mar 11; 31(3):295-304. PubMed ID: 444336
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A, Grau-Veciana JM.
    Med Clin (Barc); 1985 Jun 15; 85(3):88-91. PubMed ID: 4021630
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
    Dessibourg CA, Gachoud JP.
    Praxis (Bern 1994); 1995 Oct 24; 84(43):1235-8. PubMed ID: 7481341
    [Abstract] [Full Text] [Related]

  • 12. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J.
    Med Ann Dist Columbia; 1974 Dec 24; 43(12):587-91. PubMed ID: 4532167
    [No Abstract] [Full Text] [Related]

  • 13. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
    Yokochi M, Kondo T, Hirayama K, Narabayashi H, Kuruma I.
    No To Shinkei; 1979 Apr 24; 31(4):339-48. PubMed ID: 454549
    [No Abstract] [Full Text] [Related]

  • 14. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I, Serbănescu A, Tudorache B.
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982 Apr 24; 27(4):261-70. PubMed ID: 6222452
    [No Abstract] [Full Text] [Related]

  • 15. [The L-dopa test in Parkinson's disease].
    Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y.
    Rev Neurol (Paris); 1985 Apr 24; 141(5):413-5. PubMed ID: 4048732
    [Abstract] [Full Text] [Related]

  • 16. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O.
    Lakartidningen; 1977 Jan 05; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract] [Full Text] [Related]

  • 17. Response to Sinemet 25/100 in Parkinson's disease.
    Ulm G, Gerdes U, Lehmann K.
    Adv Neurol; 1984 Jan 05; 40():541-7. PubMed ID: 6695634
    [No Abstract] [Full Text] [Related]

  • 18. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P, Chiurulla C, Gambi D, Mennuni G, Pinto F.
    Acta Neurol Belg; 1975 Jan 05; 75(1):5-10. PubMed ID: 1202895
    [Abstract] [Full Text] [Related]

  • 19. Parkinson's disease.
    Lieberman AN.
    Compr Ther; 1986 Mar 05; 12(3):25-9. PubMed ID: 3486090
    [No Abstract] [Full Text] [Related]

  • 20. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M, Barba C, Ruggieri S, Zamponi A, Agnoli A.
    Riv Neurol; 1974 Mar 05; 44(5):303-30. PubMed ID: 4217465
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.